Pharma: Other News To Note
• UCB SA, of Atlanta, submitted regulatory filings in the U.S. and Europe to extend the marketing authorization for Cimzia (certolizumab pegol) for the treatment of adults with active psoriatic arthritis and for active axial spondyloarthritis.
